Home Health Idiopathic Pulmonary Fibrosis Pipeline Review, Therapeutics Development and Vaccine H1 2017

Idiopathic Pulmonary Fibrosis Pipeline Review, Therapeutics Development and Vaccine H1 2017


The research report “Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2017” provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Idiopathic Pulmonary Fibrosis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Complete research report on H1 2017 pipeline review of Idiopathic Pulmonary Fibrosis with 79 market data tables and 11 figures, spread across 254 pages is available at https://www.marketinsightsreports.com/reports/051811088/idiopathic-pulmonary-fibrosis-pipeline-review-h1-2017

Companies Involved in Therapeutics Development are AdAlta Ltd, Aeolus Pharmaceuticals Inc, Allinky Biopharma, apceth Biopharma GmbH, Apellis Pharmaceuticals Inc, Asahi Kasei Pharma Corp, aTyr Pharma Inc, Biogen Inc, Bioneer Corp, BLR Bio LLC, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Chiesi Farmaceutici SpA, Compugen Ltd, Cynata Therapeutics Ltd, F. Hoffmann-La Roche Ltd, FibroGen Inc, FibroStatin SL, Galapagos NV, GenKyoTex SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Global Blood Therapeutics Inc, GNI Group Ltd, Histocell SL, iBio Inc, Inventiva, Isarna Therapeutics GmbH, Kadmon Corp LLC, Kasiak Research Pvt Ltd, Kyorin Pharmaceutical Co Ltd, Lung Therapeutics Inc, Merck & Co Inc, miRagen Therapeutics Inc, MorphoSys AG, Nuevolution AB, Pharmaxis Ltd, Promedior Inc, ProMetic Life Sciences Inc, Pulmatrix Inc, Re-Pharm Ltd, Redx Pharma Plc, Respira Therapeutics Inc, Ribomic Inc, Saje Pharma LLC, Samumed LLC, Sanofi, Sorrento Therapeutics Inc, SPR Biosciences LLC, Therabron Therapeutics Inc, Unity Biotechnology Inc, Vicore Pharma AB and Yuhan Corp.

Any questions? Feel free to reach us at https://www.marketinsightsreports.com/reports/051811088/idiopathic-pulmonary-fibrosis-pipeline-review-h1-2017/inquiry

Drug Profiles discussed in this research are APL-1, ATYR-1923, BG-00011, BLR-500, BMS-986020, C-21, CC-90001, CDX-0158, CG-1011, CGEN-25009, CM-101, CT-365, CWHM-12, D-9030, FSMAB-26, FST-12, GBT-1118, GBT-440, gefapixant, GKT-831, GLPG-1690, GLPG-2938, GRC-388XX, Grx1-iSPERSE, GSK-3008348, HEC-585, HR-017, IBIOCFB-03, ICG-001, IGP-002, ISTH-0047, IVA-337, KAR-5585, KBP-7018, KD-025, lebrikizumab, LT-1001, LTI-03, MMI-0100, Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis, MOR-107, MRG-201, NAS-911, Neumomir, NUE-7770, OATD-01, OLX-101, OLX-201, omipalisib, P-013, pamrevlumab, PBF-1129, PBI-4050, pirfenidone, pirfenidone, PRI-724, PRM-151, PUR-1500, PXS-4820, RBM-005, RBM-006, Refacell-IPF, RP-0217, RT-1840, RT-234, SAR-156597, SM-04646, Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis, Small Molecules for COPD and IPF and Small Molecules for Idiopathic Pulmonary Fibrosis.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 13, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Oncology). The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Oncology) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Oncology).

This research report will help you to:-

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Please enter your comment!
Please enter your name here